Literature DB >> 31405833

Twist of Fate for Acute Promyelocytic Leukemia: TRIB3-TWIST1 Interaction Promotes Resistance.

Stephen Z Peeke1,2, Kira Gritsman3,2.   

Abstract

While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle. It is now demonstrated that TRIBBLES 3 (TRIB3) stabilizes TWIST1, leading to ATRA resistance. Peptides that disrupt this interaction lead to the degradation of TWIST1 and overcome ATRA resistance.See related article by Lin et al., p. 6228. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31405833      PMCID： PMC6801084          DOI： 10.1158/1078-0432.CCR-19-2140

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance.

Authors:  Jian Lin; Wu Zhang; Li-Ting Niu; Yong-Mei Zhu; Xiang-Qin Weng; Yan Sheng; Jiang Zhu; Jie Xu
Journal:  Clin Cancer Res       Date:  2019-06-24       Impact factor: 12.531

2.  TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.

Authors:  Ke Li; Feng Wang; Wen-Bin Cao; Xiao-Xi Lv; Fang Hua; Bing Cui; Jiao-Jiao Yu; Xiao-Wei Zhang; Shuang Shang; Shan-Shan Liu; Jin-Mei Yu; Ming-Zhe Han; Bo Huang; Ting-Ting Zhang; Xia Li; Jian-Dong Jiang; Zhuo-Wei Hu
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

3.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.

Authors:  Jae H Park; Baozhen Qiao; Katherine S Panageas; Maria J Schymura; Joseph G Jurcic; Todd L Rosenblat; Jessica K Altman; Dan Douer; Jacob M Rowe; Martin S Tallman
Journal:  Blood       Date:  2011-06-08       Impact factor: 22.113

4.  Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia.

Authors:  Priya H Dedhia; Karen Keeshan; Sacha Uljon; Lanwei Xu; Maria E Vega; Olga Shestova; Meirav Zaks-Zilberman; Candice Romany; Stephen C Blacklow; Warren S Pear
Journal:  Blood       Date:  2010-04-21       Impact factor: 22.113

Review 5.  Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.

Authors:  Akihiro Tomita; Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2013-05-14       Impact factor: 2.490

Review 6.  Acute promyelocytic leukemia: where did we start, where are we now, and the future.

Authors:  C C Coombs; M Tavakkoli; M S Tallman
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

7.  DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1.

Authors:  Jie Xu; Wu Zhang; Xiao-Jing Yan; Xue-Qiu Lin; Wei Li; Jian-Qing Mi; Jun-Min Li; Jiang Zhu; Zhu Chen; Sai-Juan Chen
Journal:  J Hematol Oncol       Date:  2016-10-10       Impact factor: 17.388

8.  TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations.

Authors:  Fang Hua; Ke Li; Jiao-Jiao Yu; Xiao-Xi Lv; Jun Yan; Xiao-Wei Zhang; Wei Sun; Heng Lin; Shuang Shang; Feng Wang; Bing Cui; Rong Mu; Bo Huang; Jian-Dong Jiang; Zhuo-Wei Hu
Journal:  Nat Commun       Date:  2015-08-13       Impact factor: 14.919
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.